Cowen and Company reaffirmed their hold rating on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a report issued on Friday morning.
“Nerve block data for Exparel is anticipated within the next month, and our consultants.”,” Cowen and Company’s analyst commented.
Several other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Pacira Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, May 2nd. Wedbush reaffirmed an outperform rating and set a $89.00 target price on shares of Pacira Pharmaceuticals in a report on Wednesday, April 19th. Leerink Swann reaffirmed a market perform rating on shares of Pacira Pharmaceuticals in a report on Monday, March 20th. Royal Bank Of Canada initiated coverage on Pacira Pharmaceuticals in a report on Thursday, April 13th. They set an outperform rating and a $58.00 target price for the company. Finally, Canaccord Genuity reaffirmed a buy rating and set a $60.00 target price on shares of Pacira Pharmaceuticals in a report on Monday, May 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $55.25.
Pacira Pharmaceuticals (PCRX) traded up 0.10% on Friday, hitting $49.20. The stock had a trading volume of 271,291 shares. The stock has a 50-day moving average of $46.14 and a 200-day moving average of $43.48. The company’s market cap is $1.97 billion. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The business had revenue of $69.30 million during the quarter, compared to analyst estimates of $70.30 million. Pacira Pharmaceuticals had a negative return on equity of 7.71% and a negative net margin of 19.26%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.15 earnings per share.
In other Pacira Pharmaceuticals news, President James S. Scibetta sold 20,000 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $51.20, for a total value of $1,024,000.00. Following the transaction, the president now directly owns 47,084 shares of the company’s stock, valued at approximately $2,410,700.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Lauren Bullaro Riker sold 601 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $26,035.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,564 shares of company stock valued at $2,506,682. Company insiders own 6.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. raised its position in shares of Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock valued at $114,000 after buying an additional 1,149 shares during the last quarter. FNY Partners Fund LP purchased a new position in shares of Pacira Pharmaceuticals during the first quarter valued at $136,000. Ameritas Investment Partners Inc. purchased a new position in shares of Pacira Pharmaceuticals during the first quarter valued at $144,000. Amalgamated Bank purchased a new position in shares of Pacira Pharmaceuticals during the first quarter valued at $204,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Pacira Pharmaceuticals during the first quarter valued at $237,000.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
